Liquidia Corporation
LQDA
Rank in Stocks
#4825
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$34.35
Last synced: 2026-10-16
Market Cap
$3.07B
Change (1 day)
-1.23%
Change (1 year)
52.81%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
EPS for Liquidia Corporation (LQDA)
EPS as of June 2026 TTM: $1.57
According to Liquidia Corporation latest financial reports and stock price the company's current EPS (TTM) is $1.57. At the end of 2023 the company had a EPS of $-1.21 an increase over its 2022 EPS that were of $-0.67.
EPS history for Liquidia Corporation from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $1.57 | -194.58% |
| 2024 | $-1.66 | 37.19% |
| 2023 | $-1.21 | 80.60% |
| 2022 | $-0.67 | -4.29% |
| 2021 | $-0.70 | -60.23% |
| 2020 | $-1.76 | -29.88% |
| 2019 | $-2.51 | -66.17% |
| 2018 | $-7.42 | 118.24% |
| 2017 | $-3.40 | 82.80% |
| 2016 | $-1.86 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.41 | 53.50% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -98.80% |
HK
|
